PERSON – Page 10

Pfizer Appoints Jeffrey Legos as New Chief Oncology Officer

3 months ago talkbio0Tagged Cancer Research, Drug Industry, Jeffrey, Leadership Change, Legos, Neoplasms, Novartis, Pfizer

Pfizer, Jeffrey Legos, Novartis, oncology, pharmaceutical industry, leadership change, cancer research

Pfizer Taps Novartis Veteran Jeffrey Legos to Lead Oncology R&D Efforts

3 months ago talkbio0Tagged Cancer Research, Drug Industry, Jeffrey, Leadership, Legos, Neoplasms, Pfizer, R&D

Pfizer, Jeffrey Legos, oncology, R&D, leadership, cancer research, pharmaceutical industry

AstraZeneca Discontinues Vemircopan, Takes $753M Charge on Former Alexion Asset

3 months ago talkbio0Tagged Alexion, AstraZeneca, charge amounts, Complement Inactivating Agents, drug discontinuation, Drug Industry, Impaired, Vemircopan

AstraZeneca, Alexion, vemircopan, complement inhibitor, drug discontinuation, impairment charge, rare diseases, pharmaceutical industry

LinusBio Introduces ClearStrand-ASD: Revolutionary Autism Diagnostic Aid Using Hair Analysis

3 months ago talkbio0Tagged Autistic Disorder, biomarker test, ClearStrand-ASD, Detection, Diagnosis, Exposome, Hair Analysis, LinusBio, Negative Predictive Value of Diagnostic Test

LinusBio, ClearStrand-ASD, autism diagnostic, hair analysis, biomarker test, early detection, negative predictive value, exposome medicine

DOGE Access to Treasury Systems Restricted Amid Concerns Over CMS Scrutiny

3 months ago talkbio0Tagged concerns, DOGE, Elon, federal, Musk secretion from Musk Deer, Myasthenic Syndromes, Congenital, Patient location type - Department, payment, Privacy

Elon Musk, DOGE, Treasury Department, CMS, payment systems, privacy concerns, lawsuit, federal court order

Pfizer Appoints Jeffrey Legos as New Chief Oncology Officer, Bolstering Cancer Drug Development Efforts

3 months ago talkbio0Tagged Antineoplastic Agents, Appointments, Drug Industry, Jeffrey, Leadership, Legos, Neoplasms, Novartis, Pfizer

Pfizer, Jeffrey Legos, oncology, cancer drug development, pharmaceutical industry, Novartis, leadership appointment

Kura Oncology and Kyowa Kirin Report Positive Phase 2 Results for Ziftomenib in AML, Prepare for FDA Submission

3 months ago talkbio0Tagged Kirin, KOMET-001, Kura Oncology, Kyowa, Leukemia, Myelocytic, Acute, NPM1, NPM1-mutant, Phase 2 trial, Submission, United States Food and Drug Administration, Ziftomenib

Ziftomenib, AML, NPM1-mutant, Phase 2 trial, KOMET-001, FDA submission, Kura Oncology, Kyowa Kirin

Kura Oncology’s Ziftomenib Achieves Phase 2 Success in AML, Paving Way for Dual-Track Phase 3 Program

3 months ago talkbio0Tagged AML, Breakthrough Therapy, DNA Sequence Rearrangement, Identifier, KMT2A gene, KOMET-001, KOMET-017, Leukemia, Myelocytic, Acute, Menin Inhibitor, Mutation, NPM1, NPM1 gene, Phase 3 trials, Ziftomenib

Ziftomenib, Acute Myeloid Leukemia (AML), NPM1 mutation, KMT2A rearrangement, Phase 3 trials, KOMET-001, KOMET-017, Menin inhibitor, Breakthrough Therapy Designation

Novo Nordisk Projects Slower Growth for 2025, Targets CagriSema Approval in 2026

3 months ago talkbio0Tagged 2025, CagriSema, Drug Industry, Growth, Nordisk, Obesity, regulatory approval, Sales - occupational activity, Wegovy

Novo Nordisk, 2025 outlook, CagriSema, obesity treatment, pharmaceutical industry, Wegovy, sales growth, regulatory approval

Boston Scientific’s Farapulse PFA System Surpasses $1 Billion in Revenue, Transforming Electrophysiology Market

3 months ago talkbio0Tagged Atrial Fibrillation, Boston Scientific, Electrophysiology (science), Farapulse, field ablation, innovation, Medical Devices, Revenue Milestone

Boston Scientific, Farapulse, pulsed field ablation, atrial fibrillation, electrophysiology, revenue milestone, medical device innovation